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ABSTRACT
Introduction: In clinical trials for knee
osteoarthritis (OAK), rescue medication is com-
monly provided to manage uncontrolled index-
knee pain. The impact of treatment on rescue
medication utilization provides important infor-
mation on the robustness of analgesic effect. In
randomized controlled OAK trials (NCT01487161,
NCT02116972, NCT02357459), intra-articular
(IA) triamcinolone acetonide extended-release
(TA-ER) demonstrated substantial, prolonged
analgesia versus saline-placebo and TA crystalline
solution (TAcs) as assessed by patient-reported
pain scales. This pooled analysis assessed the
impact of TA-ER on rescue medication use.
Methods: Patients (N = 798) with OAK (Ameri-
can College of Rheumatology criteria;
Kellgren–Lawrence grade 2/3) and baseline
average daily pain intensity score C 5 to B 9
(0–10 numeric rating scale) received a single IA
injection of TA-ER (N = 324), saline-placebo
(N = 262), or TAcs (N = 212). Acetaminophen/
paracetamol tablets were provided to treat
uncontrolled pain (knee or otherwise). Rescue
medication consumption was monitored through
a daily diary; pill counts were confirmed at the
clinical site. Differences in rescue medication use
were measured by least-squares mean (LSM) dif-
ferences, number of rescue medication tablets
used per day, and in area under the effect (AUE)
curves of rescue medication tablets used per week.
Results: The overall number of rescue medica-
tion tablets used per day through week 24 was
significantly less (p B 0.05) for TA-ER versus
saline-placebo (LSM difference, - 0.43) and
TAcs (- 0.24). Rescue medication use was sig-
nificantly (p B 0.05) lower following TA-ER
versus saline-placebo across weeks 1–12
(AUEweeks1–12; LSM difference, - 24.5) and
weeks 1–24 (AUEweeks1–24; - 51.6) and versus
TAcs across weeks 1–12 (AUEweeks1–12; - 21.1).
Conclusions: In patients with painful OAK,
reduced rescue medication use may be a potential
benefit of TA-ER and further supports its analgesic
efficacy. Additional research is needed to assess
whether TA-ER impacts the use of other common
oral analgesics (nonsteroidal anti-inflammatory
drugs, opioids) for patients with OAK.
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PLAIN LANGUAGE SUMMARY
Osteoarthritis is a common chronic condition
that results from the breakdown of cartilage
within the joint, leading to pain, swelling, and
joint stiffness. There are no drugs that can pre-
vent or cure osteoarthritis, but treatments are
available to reduce osteoarthritis pain, includ-
ing acetaminophen, nonsteroidal anti-inflam-
matory drugs, opioids, viscosupplementation,
and steroid injections. Steroid injection into the
affected joint of a patient with knee
osteoarthritis has been shown to reduce pain;
however, because of the rapid outflow of drug
from the joint, only short-term pain relief is
achieved. A long-acting form of steroid that
releases the active treatment slowly over time
from a biodegradable bead has been shown to
be effective in knee osteoarthritis. Compared
with a short-acting steroid treatment, this
extended-release formulation results in a longer
presence of active steroid in the joint following
injection. This extended-release steroid has also
produced improved pain relief compared with a
saline-placebo injection and a short-acting
steroid injection as measured by patient-
reported pain scales. Another way to measure
the impact of treatment on osteoarthritis pain is
to monitor the use of ‘‘rescue’’ medication pro-
vided to participants receiving treatment during
trials in case they need to manage uncontrolled
index-knee pain. In the current analysis, the
extended-release steroid injection reduced the
need for such rescue medication, compared
with both saline-placebo and a short-acting
steroid injection. Reduced use of rescue medi-
cation can indicate improved pain relief and
can also limit patient use of secondary medica-
tions that may have harmful side effects.
INTRODUCTION
Osteoarthritis of the knee (OAK) is a painful
condition that contributes to reduced mobility
and impaired quality of life [1, 2]. Symptomatic
OAK is typically managed with analgesics,
including oral agents [e.g., acetaminophen,
nonsteroidal anti-inflammatory drugs (NSAIDs),
and opioids] and standard intra-articular corti-
costeroid (IACS) injections [2–4]. Although oral
pain-relieving agents can be effective in allevi-
ating OAK pain, a number of associated adverse
effects limit their long-term use [2, 4–7]. Con-
ventional IACS injections reduce pain and
improve function in OAK; however, the anal-
gesic effect of standard IACS, such as triamci-
nolone acetonide crystalline suspension (TAcs),
may be of limited duration because of the rapid
egress of corticosteroid from the joint space
following injection [8–10]. Longer-acting IA
pain relief treatments that reduce the long-term
use of oral analgesics are needed for the man-
agement of patients with chronic OAK pain.
Triamcinolone acetonide extended-release
(TA-ER) is a microsphere-enabled [75:25
poly(lactic-co-glycolic acid), nominal drug load
of 25% (w/w)] longer-acting IA agent. Pharma-
cokinetic data show that TA joint residency
time increased and systemic exposure decreased
following TA-ER injection compared with stan-
dard TAcs in patients with OAK [10]. This
reduced systemic release of TA following TA-ER
has been observed in several studies and may
contribute to the reduced glycemic control dis-
ruption observed with TA-ER compared with
TAcs treatment in patients with OAK and type 2
diabetes [10–13]. The local synovial fluid TA
concentration profile following TA-ER injection
is in line with the prolonged, clinically mean-
ingful efficacy observed in randomized con-
trolled trials of patients with OAK [13–15]. In a
phase 3 study, TA-ER significantly improved
mean average daily pain (ADP) intensity score
compared with saline-placebo at the 12-week
primary endpoint (p\0.0001) and provided
continued significant improvements to week 16
(p\ 0.05) [14]. TA-ER also provided significant
improvements in the Western Ontario and
McMaster Universities Osteoarthritis Index
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(WOMAC)-A (pain), -B (stiffness), and
-C (function) and in the Knee Injury and
Osteoarthritis Outcome Score-Quality of Life
scores compared with both saline-placebo and
TAcs at week 12 (p\ 0.05; prespecified
exploratory endpoints) [14]. In the same study,
TA-ER demonstrated an acceptable safety profile
and most adverse events (AEs) were grade 1 or 2
and nonserious [14].
It is common in clinical trials of analgesic
agents for rescue medication to be issued to
participants for use as needed to manage
uncontrolled index-knee pain [16]. Measuring
rescue medication use can provide important
information on the robustness of the overall
analgesic effect because effective pain medica-
tions should reduce the need for rescue medi-
cation. According to guidance from the US Food
and Drug Administration, rescue medication
can be used to define a ‘‘responder’’ in clinical
studies and can be used as a primary outcome
measure and, furthermore, rescue medication
use should be considered a secondary endpoint
when pain intensity is the primary efficacy
endpoint [17]. The use of rescue medication is
frequently cited as a secondary endpoint or an
additional efficacy measure in clinical trials
evaluating the efficacy of other IA agents for
OAK [18–23]. However, evidence is limited
regarding the impact of conventional IACS on
rescue medication use. One meta-analysis
reported no difference in the proportion of
rescue medication use with IA injection of
conventional IACS [18]. Conversely, in a phase 3
study of TA-ER, rescue medication (ac-
etaminophen/paracetamol) was provided to
patients to manage uncontrolled index-knee
pain, and use was evaluated as an additional
efficacy endpoint; significantly fewer rescue
medication tablets were needed per week by
patients treated with TA-ER than by those trea-
ted with saline-placebo through week 24
(p\ 0.05) [14]. To better understand the impact
of TA-ER treatment on the need for rescue
medication across the TA-ER clinical program, we
pooled available study data from three phase 2/3
studies and evaluated rescue medication use in
patients with OAK.
METHODS
Compliance with Ethics Guidelines
All procedures were conducted in accordance
with the ethical standards of the responsible
committee on human experimentation (insti-
tutional and national) and with the Helsinki
Declaration of 1964, as revised in 2013. Protocols
of the three clinical studies (ClinicalTrials.gov
identifiers: NCT01487161, NCT02116972, and
NCT02357459) contributing information to the
pooled analyses were approved by governing
ethics bodies at the participating sites, and
patients provided written informed consent
before participating in any study-related
procedures.
Study Design
Full details on patient eligibility, study design,
and interventions in the phase 2 [13], phase 2b
[15], and phase 3 [14] clinical trials included in
this pooled analysis have been reported and are
briefly summarized here. All studies enrolled
men and women C 40 years of age whose body
mass index was B 40 kg/m2. Participants had
symptomatic OAK as defined by American Col-
lege of Rheumatology OA criteria for
C 6 months [24], Kellgren–Lawrence grade 2/3
OA based on screening index-knee radiography
[25], and baseline ADP intensity score C 5 to
B 9 (0–10 numeric rating scale) for C 5 of the
previous 7 days [26, 27]. Each trial used a
similar multicenter, double-blind, randomized,
parallel-group, controlled design. In each trial,
patients were evaluated every 4 weeks following
a single IA injection through 12 or 24 weeks.
Data from patients treated with saline-placebo,
TAcs 40 mg, and TA-ER 32 mg (delivered dose)
were pooled for the purposes of this analysis.
Concomitant Medication
The following analgesics were considered
restricted medications and were not to be taken
or used during the studies: oral NSAIDs, aspirin
([325 mg/day), centrally acting pain medica-
tions (e.g., pregabalin, gabapentin, duloxetine,
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milnacipran), opioids, and topical therapies
(e.g., topical NSAIDs, capsaicin, lidocaine pat-
ches, other local treatments) applied to the
index knee. Rescue analgesic medication (ac-
etaminophen/paracetamol 500-mg tablets) was
issued to patients for use on an as-needed basis
to manage uncontrolled index-knee pain or any
other type of pain, and was not to be used for
prophylaxis. Consumption of rescue medica-
tion was monitored through a daily diary
reporting system, and pill counts were con-
firmed at the clinical site.
Study Assessments
The objective of the pooled analysis was to
examine rescue medication use in three phase 2/3
clinical trials. Results from all three studies con-
tributed to the findings for weeks 1–12 and results
from the phase 2b/3 studies contributed to the
findings from weeks 1–24. The mean number of
rescue medication tablets used per week was
computed for each patient by summing the
number of tablets used in each weekly interval
and dividing by the number of days of non-
missing responses in the weekly interval.
Treatment-emergent AEs (TEAEs)—defined
as any AE with onset after the administration of
study treatment or any AE that was present at
baseline but worsened in intensity through the
end of the study—were analyzed.
Statistical Analysis
Effects of IA injection treatment on rescue
medication use were measured by least-squares
means (LSM) at each week through week 24 for
TA-ER versus saline-placebo and TAcs, analyzed
with mixed effects model for repeated-measures
methodology on observed data with no impu-
tation for missing data. Area under the effect
(AUE) curves of rescue medication use for TA-ER
versus saline-placebo and TAcs through week 12
(AUEweeks1–12) and week 24 (AUEweeks1–24) were
analyzed using analysis of covariance, with
study site as a covariate.
RESULTS
Demographics and Baseline Disease
Characteristics
The pooled analysis included a total of
798 patients, with more patients receiving
TA-ER (N = 324) than saline-placebo (N = 262)
or TAcs (N = 212). Across the three studies,
demographic and baseline disease characteris-
tics were well balanced for the three treatment
groups, including similar baseline ADP intensity
scores (Table 1). Most patients were female
(58.6%) and white (84.3%). Mean body mass
index at baseline was 30.55, 30.58, and
30.15 kg/m2, and OAK was Kellgren–Lawrence
grade 3 in 60.8, 59.5, and 58.0% of patients in
the TA-ER, saline-placebo, and TAcs treatment
groups, respectively.
Rescue Medication Use
The use of rescue medication decreased follow-
ing IA injection (Fig. 1a). The overall average
number of rescue medication tablets used per
day through 24 weeks [LSM (standard error, SE)]
was 0.89 (0.090) for TA-ER compared with 1.32
(0.100) for saline-placebo, and the total LSM
difference (95% CI) was - 0.43 (- 0.65, - 0.20;
p = 0.0002) for TA-ER compared with saline-
placebo (Fig. 1b). Fewer rescue medication
tablets were used per week by patients treated
with TA-ER than saline-placebo at all time
points, and the decreased use was significant
(p\ 0.05) at each of weeks 1–16 and 19–20
(Fig. 1a). Rescue medication use was also
statistically significantly lower with TA-ER than
with saline-placebo across weeks 1–12
(AUEweeks1–12; LSM difference, - 24.5; p = 0.0121)
and weeks 1–24 (AUEweeks1–24; LSM difference,
- 51.6; p = 0.0023; Table 2).
The overall average rescue medication tablets
used per day through 24 weeks was lower for
TA-ER with an LSM (SE) of 0.89 (0.090) com-
pared with 1.13 (0.113) for TAcs, and a total
LSM difference (95% CI) through week 24 of
- 0.24 (- 0.48, - 0.01; p = 0.0433) for TA-ER
compared with TAcs (Fig. 1b). TA-ER treatment
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reduced rescue medication use compared with
TAcs at each week through week 24, with the
difference reaching significance (p\0.05) at
weeks 6, 7, and 10 (Fig. 1a). TA-ER also signifi-
cantly reduced rescue medication use across
weeks 1–12 (AUEweeks1–12; LSM difference,
Table 1 Pooled demographic and baseline characteristics
TA-ER 32 mg
N = 324
Saline-placebo
N = 262
TAcs 40 mg
N = 212
Sex, n (%)
Male 139 (42.9) 105 (40.1) 86 (40.6)
Female 185 (57.1) 157 (59.9) 126 (59.4)
Age, years, mean (SD) 60.5 (9.16) 61.4 (8.73) 62.1 (10.06)
Race, n (%)
American Indian or Alaska Native 0 1 (0.4) 0
Asian 23 (7.1) 15 (5.7) 18 (8.5)
Black or African American 26 (8.0) 19 (7.3) 13 (6.1)
Native Hawaiian or other Paciﬁc Islander 4 (1.2) 1 (0.4) 2 (0.9)
White 269 (83.0) 226 (86.3) 178 (84.0)
Other 2 (0.6) 0 1 (0.5)
BMI (kg/m2), mean (SD) 30.55 (4.771) 30.58 (4.871) 30.15 (4.864)
BMI category, n (%)
Normal (18.0–24.9 kg/m2) 43 (13.3) 32 (12.2) 34 (16.0)
Overweight (25.0–29.9 kg/m2) 114 (35.2) 91 (34.7) 69 (32.5)
Class I obese (30.0–34.9 kg/m2) 100 (30.9) 81 (30.9) 72 (34.0)
Class II obese (35.0–39.9 kg/m2) 65 (20.1) 57 (21.8) 37 (17.5)
Morbid obesity (C 40.0 kg/m2) 2 (0.6) 1 (0.4) 0
Years since primary diagnosis, mean (SD) 7.10 (6.736) 6.50 (5.781) 7.35 (6.944)
Kellgren–Lawrence grade, n (%)
2 127 (39.2) 106 (40.5) 88 (41.5)
3 197 (60.8) 156 (59.5) 123 (58.0)
4 0 0 1 (0.5)
Weekly average daily pain intensity score
5–5.9 118 (36.4) 99 (37.8) 82 (38.7)
6–6.9 107 (33.0) 78 (29.8) 70 (33.0)
C 7 99 (30.6) 85 (32.4) 60 (28.3)
BMI body mass index, SD standard deviation, TAcs triamcinolone acetonide crystalline suspension, TA-ER triamcinolone
acetonide extended-release
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- 21.1; p = 0.0424) and numerically reduced
medication use across weeks 1–24 (AUEweeks1–24;
LSM difference, - 32.2; p = 0.0731; Table 2).
Safety
Pooled safety data from the trials are presented
in Table 3. Most TEAEs were grade 1 or 2, and
there were no deaths. The incidence of TEAEs
(51.9, 49.2, and 56.1%, respectively) and serious
TEAEs (3.1, 1.1, and 1.9%, respectively) was
similar across the TA-ER, saline-placebo, and
TAcs groups. Few patients discontinued because
of TEAEs (1.2, 0.8, and 0.5% in the TA-ER,
saline-placebo and TAcs groups, respectively).
Fig. 1 Rescue medication (acetaminophen/paracetamol
500-mg tablets) use following IA treatment. a Average
rescue medication tablets used per day in each weekly
interval. b Average rescue medication tablets used per
day through 24 weeks. *p\ 0.05 versus saline-placebo.
p\ 0.05 versus TAcs. IA intra-articular, SE standard
error, TAcs triamcinolone acetonide crystalline suspension,
TA-ER triamcinolone acetonide extended-release
Table 2 Area under the effect curve of average rescue medication use
TA-ER 32 mg
N = 324
Saline-placebo
N = 262
TAcs 40 mg
N = 212
AUEweeks1–12
LSM (SE) 82.6 (7.81) 107.1 (8.57) 103.7 (9.74)
LSM difference vs. saline-placebo (p value) - 24.5 (0.0121)
LSM difference vs. TAcs (p value) - 21.1 (0.0424)
AUEweeks1–24
LSM (SE) 135.6 (13.48) 187.2 (14.80) 167.9 (16.82)
LSM difference vs. saline-placebo (p value) - 51.6 (0.0023)
LSM difference vs. TAcs (p value) - 32.2 (0.0731)
AUE area under the effect curve, LSM least-squares mean, SE standard error, TAcs triamcinolone acetonide crystalline
suspension, TA-ER triamcinolone acetonide extended-release
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DISCUSSION
In this pooled analysis of three phase 2/3 clini-
cal trials, TA-ER provided pain relief as shown
by significant and sustained reductions in res-
cue medication use from baseline. In addition,
patients treated with TA-ER required less rescue
medication throughout the studies than
patients treated with saline-placebo or TAcs.
The safety profiles of TA-ER, saline-placebo, and
TAcs were similar in this pooled analysis and
consistent with that in the individual studies.
Providing rescue medication to patients
participating in OA clinical trials can prevent
dropout due to episodes of acute breakthrough
pain or lack of efficacy and can provide an
alternative way of measuring pain relief across
treatment arms. The use of rescue medication is
a clinically important indicator of analgesic
efficacy and can be a secondary or an explora-
tory outcome measure in OA studies [16, 17].
The current analysis adds to the efficacy profile
of TA-ER by demonstrating a reduced need for
secondary pain medication, which would
potentially lower the cumulative exposure of a
patient to the adverse effects of oral agents
[13, 14].
The current analysis is limited by its pooled
retrospective nature. This led to differences in
the number of patients receiving each treat-
ment because of differences in individual study
designs and durations. In addition, the allow-
ance to use rescue medication for any worsen-
ing pain, not limited to OA knee pain, may have
confounded the results; however, given the fact
that these were large randomized trials, the
impact of this potential confounder was con-
sidered to be minimal.
CONCLUSIONS
In patients with painful OAK, TA-ER treatment
reduced rescue medication use compared with
saline-placebo and TAcs. These findings provide
another indication of analgesic benefit of TA-ER
Table 3 Summary of adverse events
TA-ER 32 mg
N = 324
Saline-placebo
N = 262
TAcs 40 mg
N = 212
C 1 TEAE, n (%) 168 (51.9) 129 (49.2) 119 (56.1)
Grade 1 78 (24.1) 51 (19.5) 54 (25.5)
Grade 2 77 (23.8) 65 (24.8) 59 (27.8)
Grade 3 11 (3.4) 13 (5.0) 4 (1.9)
Grade 4 2 (0.6) 0 2 (0.9)
C 1 serious TEAE 10 (3.1) 3 (1.1) 4 (1.9)
C 1 TEAE leading to study discontinuation 4 (1.2) 2 (0.8) 1 (0.5)
TEAE by maximum relationship
Not related 133 (41.0) 108 (41.2) 93 (43.9)
Unlikely 18 (5.6) 13 (5.0) 13 (6.1)
Possibly, probably, or deﬁnitely related 17 (5.2) 8 (3.1) 13 (6.1)
C 1 index-knee TEAE 53 (16.4) 37 (14.1) 22 (10.4)
C 1 index-knee TEAE leading to study discontinuation 3 (0.9) 2 (0.8) 1 (0.5)
TAcs triamcinolone acetonide crystalline suspension, TA-ER triamcinolone acetonide extended-release, TEAE treatment-
emergent adverse event
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beginning at week 1 and lasting throughout
24 weeks. Reducing concomitant analgesic
medication use in this patient population may
be an additional benefit of TA-ER treatment.
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